Justin Ho


Dr. Justin Ho is a Principal in the Life Sciences Practice. He specializes in industrial organization and the economic and strategic evaluation of firm behavior and contracting.

Dr. Ho’s research includes the welfare and competitive effects of new product and contract introduction. He has worked on matters involving a range of products, including biologics, small-molecule drugs, and medical devices. His experience includes disputes on efforts in drug development (including the license disputes and interpretation), antitrust matters (market definition and damages in reverse-payment settlements, and product tying), intellectual property disputes (evaluation of commercial success, reasonable royalty, and lost profit analyses), pricing (price fixing and welfare analyses), and product labeling matters (including both consumer and pharmaceutical product claims).

Selected Engagements

  • 01
    Endo and Opana ER ANDA challenge
    CRA consultants supported Endo International plc (Endo) in its successful challenge of products that infringed on its patents covering Opana® Extended Release...
    View engagement
  • 02
    CRA addresses U.S. government healthcare programs and pharmaceutical pricing in False Claims Act suit
    In this whistleblower suit, a relator alleged Bristol-Myers Squibb Co. (“BMS”) violated the False Claims Act and various state claims. The suit alleged that...
    View engagement
  • 03
    CRA assess causality in pharmaceutical Lanham Act case
    In the context of a Lanham Act case, CRA assessed whether market performance for a hospital-based pharmaceutical product was affected by alleged improper...
    View engagement